Prescient Healthcare Group has completed the integration of recently acquired businesses Uptake and Dolon under a single global Prescient brand.
Shutterstock - claudenakagawa
The rebrand marks the final stage of integrating the three businesses following Prescient's acquisitions of Uptake and Dolon, providing clients with a single point of access to expertise spanning the pharmaceutical product lifecycle.
Jason McKenna, chief executive officer of Prescient, said: "What began as an expansion of our capabilities has become something much more powerful. Over the past several months, the Prescient, Dolon and Uptake teams have been working together to solve increasingly complex challenges for clients. Bringing everything together under the Prescient name reflects how the platform works today, as one integrated organisation combining specialist expertise across commercial, medical and market access disciplines."
The unified business supports pharmaceutical and biotechnology companies from early clinical development through product launch and lifecycle management. Prescient said the integrated structure enables multidisciplinary teams to address increasingly connected commercial, scientific and market access challenges facing the industry.
The move also simplifies how clients engage with the business, bringing together capabilities across:
- Commercial Strategy and Planning
- Competitive Strategy
- Medical Affairs and Real-World Evidence
- Value, Pricing and Access
Debbie Allman, Prescient’s chief growth officer and global practice lead, Commercial, said: "Our clients don't experience challenges in functional silos. Scientific, commercial, competitive and access decisions increasingly influence one another. Our role is to connect those perspectives in practical ways that help clients make stronger decisions and execute with confidence."
The integration follows a period of operational alignment between the three organisations and establishes a single global Prescient brand across its seven international offices.